CCCC vs ARVN

For growth investors, C4 Therapeutics, Inc.

(CCCC) is the stronger pick with 1. 0% revenue growth year-over-year, versus -0. 3% for Arvinas, Inc. (ARVN). Analysts rate C4 Therapeutics, Inc. (CCCC) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arvinas, Inc.

(ARVN) delivered a total return of -83. 8%, compared to -91. 2% for C4 Therapeutics, Inc. (CCCC). Over 10 years, the gap is even starker: ARVN returned -36. 1% versus CCCC's -88. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arvinas, Inc.

(ARVN) is the lower-risk stock at 1. 15β versus C4 Therapeutics, Inc. 's 2. 35β — meaning CCCC is approximately 105% more volatile than ARVN relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 23% for C4 Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), C4 Therapeutics, Inc.

(CCCC) is pulling ahead at 1. 0% versus -0. 3% for Arvinas, Inc. (ARVN). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to 16. 4% for C4 Therapeutics, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arvinas, Inc.

(ARVN) is the more profitable company, earning -30. 8% net margin versus -292. 1% for C4 Therapeutics, Inc. — meaning it keeps -30. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARVN leads at -43. 8% versus -290. 7% for CCCC. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arvinas, Inc.

(ARVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15)). C4 Therapeutics, Inc. (CCCC) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARVN: -36. 1%, CCCC: -88. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.